Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the phase 2 FREEDOM-3 trial and preclinical studies of the cell therapy FCR-001.
“We’re exploring addressing other settings where allogeneic stem cell transplant has been a standard of care. There are other nonmalignant hematological or immune disorders, in which stem cell transplants replace diseased cells with healthy cells from a healthy donor. The potential to do so with nonmyeloablative conditioning and across HLA mismatch barriers would makeit easier to find a pool of eligible donors and that would be an important advance."
Talaris Therapeutics is working toward being able to reprogram the immune system for a variety of immune indications.So far, their work in solid organ transplant has shown promise in chimerizing the immune system to tolerate both donor and host cells.1
Talaris is evaluating their cell therapy candidate FCR-001 in their lead program for living kidney transplant, another program in diffuse cutaneous systemic sclerosis (dcSSc), and a preclinical program in deceased kidney transplant.2
GeneTherapyLive spoke with Scott Requadt, chief executive officer, Talaris Therapeutics, to learn more about the FREEDOM-3 trial assessing FCR-001 in dcSSc and how the cell therapy candidate could improve outcomes in these patients. He also discussed advantages of Talaris’ in-house cell manufacturing and the preclinical program in deceased kidney transplant.
Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL
December 7th 2024In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.